Drugs in the blood Flashcards

1
Q

two stages of hemostasis and what happens during them

A

i. Vasospasm (vasoconstriction)
-Immediate; restricts blood flow
-Sympathetics and local factors eg. thromboxane
-Myogenic properties of vessel wall

ii. Platelet response
-Within seconds; forms initial plug
-Platelets adhere to exposed collagen of damaged endothelium, and each other
-Platelet plug releases chemical mediators (TXA2, 5-HT and ADP)
(recruit more platelets, promote vasoconstriction, initiate the coagulation cascade)

ii. Coagulation Phase
-Occurs thru sequential conversion of inactive proteins into catalytically active proteases
-Tissue factor-factor VIIa pathway is main initiator
-Result—conversion of soluble fibrinogen to insoluble fibrin—net of organized protein around platelet plug
-Result of coagulation phase is clot proper (thrombus)

iv. Clot dissolution (Fibrinolysis)
-Wound healing and restoration of blood flow
-Dissolution of clot by proteolytic actions of plasmin bound to clot process of fibrinolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

2 goals of normal hemostasis

A

§ Prevent prolonged hemorrhage
§ Prevent spontaneous thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

prothrombogenic factors (4)

A

Platelet Activators
Procoagulants
Vasoconstriction
Fibrinolytic Inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

antithrombogenic factors (4)

A

Platelet Inhibitors
Anticoagulants
Vasodilators
Fibrinolytic Activators

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

causes of excessive bleeding (3)

A

Platelet deficiency
-Thrombocytopenias (quantitative consumption)
-von Willebrand’s (qualitative disorder)

Clotting factor deficiency
-Single factor eg. hemophilia (VIII, IX)
-Multiple factors ie. vitamin K deficiency

Fibrinolytic hyperactivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

mechanism of action of Vitamin K for hemorrhagic diseases

A

Confers biological activity: factors II, VII, IX, X; post-translational modification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

forms of vitamin K

A

-Vitamin K1: phytonadione (foods)
-Vitamin K2: menaquinone (intestinal bacteria)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

uses of vitamin K

A

Vitamin K deficiency
-Rodenticide toxicity
-Dicumoral toxicity (sweet clover poisoning)

Warfarin overdosing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

oral vs parenternal route of vitamin K administration

A
  • Intravenous route—best to avoid; anaphylaxis possible
  • IM route- hematoma possible; SC recommended route
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what does vitamin K require for intestinal absorption

A

bile salts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

desmopressin acetate (DDAVP); uses, how it works, forms

A
  • Transiently increases von Willebrand activity in mild von Willebrand disease
  • Used prophylactically to control capillary bleeding during surgery
    (Effects are short lived (2 hrs); repeat dosing—reduced effect)
  • Available as injectable or nasal spray (can be given SC)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is protamine sulfate used for and how does it work

A

to treat heparin doses

-binds to heparin neutralizing its anticoagulant effects
-More effective against large molecular weight heparin molecules in unfractionated heparins versus the low molecular weight heparins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

two things to consider and why for administering protamine sulfate

A
  • Give IV slowly to avoid adverse reactions that can include collapse
  • Accurate dosing needed; high doses can produce anticoagulant
    effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

how do fibrinolytic inhibitors work

A
  • Plasmin lyses fibrin and fibrinogen
    Attaches to fibrin via lysine binding sites
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is aminocaproic acid (amicar) used for and how does it work

A

-Synthetic agent similar to lysine; blocks lysine binding site
-Competitively inhibits plasmin action on fibrin
-Incomplete lysis can lead to thrombi formation

Uses
* Bleeding from fibrinolytic therapy
* Adjunct therapy-hemophiliacs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

three drug classes for thromboembolic disease

A

— Systemic anticoagulants
— Antithrombotic drugs
— Fibrinolytic drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

venous vs arterial thrombus

A

-Red thrombus-fibrin rich, large # RBCs; venous
-White thrombus-platelet rich; arterial

17
Q

three prothrombic factors

A

-Local vessel injury
-Abnormal blood flow (stasis or turbulence)
-Altered blood coagulability (Hyperactivity of hemostatic mechanisms, Hypoactivity of fibrinolytic mechanisms)

18
Q

ideal systemic anticoagulant… (2)

A

-Prevent pathologic thrombosis
-Allow normal response to vascular injury and limit bleeding

19
Q

mechanism of action of heparin (unfractionated)

A

-Enhances (accelerates 100-fold) the action of Antithrombin III (AT-III)—forms heparin-ATIII complex

-AT- III inhibits activated clotting
factors especially thrombin (IIa) and
Xa—acts as a “suicide substrate”

20
Q

uses of heparin

A

Primarily used in the initial treatment of thrombosis and thromboembolic disease
—

-Rapid onset of action renders it useful as an “acute anticoagulant”
(Oral anticoagulant usually given concurrently)

-Prevents new thrombus formation only !! (Does not lyse existing thrombus)

21
Q

adverse effects of heparin

A

-Bleeding tendencies
-Monitor aPTT; 1.8-2.5X normal mean aPTT
-Protamine sulfate can neutralize heparin in overdose

22
Q

advantages of low molecular weight heparins (enoxaparin) compared to unfractionated heparin

A

-Less bleeding tendencies possible
-Protamine sulfate is less active against LMW heparins
-Less risk of thrombocytopenia
-Improved pharmacokinetics– can give subcutaneous

23
Q

adverse effects of warfarin

A

-Bleeding tendencies; can combat with Vitamin K1
-Serious bleeding requires fresh blood/plasma
-Warfarin crosses the placenta; don’t use in pregnancy; Heparin does not cross the placenta

24
Q

how warfarin works

A

Oral anticoagulant by antagonizing vitamin K actions
-Reduces clotting factors (II, VII, IX and X); factor VII has shortest half-life
-Clotting not affected until existing factors used

25
Q

what class is rivaroxaban

A

selective factor Xa inhibitors

26
Q

how does rivaroxaban work

A

-Inactivate factor Xa directly
-Does not interact with ATIII and no thrombin activity
-Fairly quick anticoagulant activity

27
Q

how does aspirin work

A

Irreversibly binds (acetylates) cyclooxygenase-1
-COX-1 selective over COX-2 at low doses; selectivity lost at higher doses
-Prevents TXA2 production in platelets reducing platelet aggregation
-Other NSAIDs can inhibit cyclooxygenase-1 but not irreversibly; hence a shorter duration of action
-Cat metabolizes aspirin poorly; 2X weekly dosing used

28
Q

uses of aspirin

A

-Feline cardiomyopathy
-Heartworm disease
-Equine laminitis and navicular diseases

29
Q

adverse effects of aspirin

A
  • Gastrointestinal ulceration
  • Renal damage
  • Bleeding tendencies
30
Q

how does clopidogrel work

A

Reduce platelet aggregation by inhibiting ADP pathways

-Act as P2Y 12 (aka P2YADP ) receptor antagonists; prevent binding of ADP to receptors
-May be synergistic with aspirin as work by different mechanisms of action
-Clopidogrel is irreversible inhibitor of the P2Y 12 receptor

31
Q

what type of drug is clopidogrel

A

ADP inhibitor

32
Q

what is clopidogrel used for

A

Clopidogrel is routinely used for thromboembolic concerns in cats (HCM) and in dogs (mainly IMHA)

33
Q

how do fibrinolytic drugs work

A

Fibrinolytics rapidly lyse thrombi by activating plasmin from clot bound
plasminogen

34
Q

uses of tissue plasminogen activator

A

Thromboembolic therapy for canine pulmonary thromboembolism and feline saddle thrombis

35
Q

adverse effects of of tissue plasminogen activator

A
  • Reperfusion injury
  • Bleeding tendencies
36
Q

how tissue plasminogen activator works

A

-Are proteases that bind fibrin
-Can preferentially activate clot bound plasminogen (Limits activation of systemic plasmin)
-Fairly short half-life necessitates constant rate infusion

37
Q

adverse effects of EPO

A
  • Hypertension and seizure possible
  • Therapeutic failure from antibody formation most common
38
Q

how does EPO work

A

Glycoprotein made by kidney in response to hypoxia
-Prepared by recombinant technology (rHuEPO)
-EPO receptor is member of JAK/STAT superfamily
-Stimulates proliferation differentiation of red cell progenitors and release of reticulocytes

39
Q

use of EPO

A
  • RhuEPO used primarily in chronic anemia due to erythropoietin production in Chronic renal failure
  • Has been used in anemia of other causes eg. Cancers
40
Q

considerations when giving EPO

A
  • Increase in hematocrit and hemoglobin in 2-4 weeks
  • Iron supplementation is advised with EPO therapy